Jan has more than 20 years’ experience of building and leading cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of multiple therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer during a 5 year period from company start up through to successful IPO, overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple roles spanning from Discovery to Manufacturing environments, including senior leadership roles in the rapidly growing Biopharma business. Latterly, Jan oversaw the establishment of the Cell & Gene Therapy platform unit and played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.
Rob joined TVI as Senior Partner in 2018. In addition to serving as Board Director or Observer at the Board of seven TVI portfolio companies, Rob led the formation and fundraising for TranSINE Therapeutics. Prior to joining TVI, Rob was Director of Healthcare Investments at Touchstone Innovations, and he was central to the formation of a number of now well-established UK biotech companies including Mission Therapeutics, Crescendo Therapeutics and Storm Therapeutics.
Christian joined the DDF as Partner in 2019 and led the investment in Transine. Christian joined the DDF from Wellington Partners and before that was a Senior Investment Manager with High-Tech Gründerfonds where he completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics (acquired by Boehringer Ingelheim in 2019), Rigontec (acquired by MSD in 2017) and Cunesoft (acquired by Phlexglobal in 2019).
With significant experience in both industrial and academic research, Mike has published extensively on genomic analysis and cancer research. Combining his research skills with his significant experience in business development, in 2010 Mike founded and became CEO of Cell Guidance Systems which has developed a plug-and-play protein therapeutic platform that offers potential for many intractable diseases.
A clinician by training, Alan is a highly experienced individual who has led the development of a gene-based medicine portfolio and has significant experience in large pharma, biotech and academia. Alan brings significant expertise in viral delivery for projects across a range of therapeutic areas. His expertise in medicines development has been recognised with an Honorary Professorship at the University of Birmingham and in 2014 he was elected Fellow of the Royal Society of Biology.